European Union - English - EMA (European Medicines Agency)

sanofi pasteur - hepatitis b surface antigen, diphtheria toxoid, tetanus toxoid, bordetella pertussis antigens pertussis toxoid filamentous haemagglutinin, poliovirus (inactivated) type 1 (mahoney) type 2 (mef-1) type 3 (saukett), haemophilus influenzae type b polysaccharide (polyribosylribitol phosphate) conjugated to tetanus protein - hepatitis b; tetanus; immunization; meningitis, haemophilus; whooping cough; poliomyelitis; diphtheria - vaccines, bacterial and viral vaccines, combined - hexacima (dtap-ipv-hb-hib) is indicated for primary and booster vaccination of infants and toddlers from six weeks of age against diphtheria, tetanus, pertussis, hepatitis b, poliomyelitis and invasive diseases caused by haemophilus influenzae type b (hib).the use of this vaccine should be in accordance with official recommendations.

Israel - English - Ministry of Health

kamada ltd, israel - human hepatitis b immunoglobulin - solution for injection - human hepatitis b immunoglobulin 500 iu - hepatitis b immunoglobulin - hepatitis b immunoglobulin - prevention of hepatitis b virus (hbv) re-infection in hbsag and hbv-dna negative adult patients at least one week after liver transplantation for hepatitis b induced liver failure.hbv-dna negative status should be confirmed within the last 3 months prior to olt. patients should be hbsag negative before treatment start.the concomitant use of adequate virostatic agents should be considered as standard of hepatitis b re-infection prophylaxis.

European Union - English - EMA (European Medicines Agency)

glaxosmithkline biologicals s.a. - hepatitis a virus (inactivated), hepatitis b surface antigen - hepatitis b; hepatitis a; immunization - vaccines - ambirix is for use in non-immune persons from one year up to and including 15 years of age for protection against hepatitis-a and hepatitis-b infection.protection against hepatitis-b infections may not be obtained until after the second dose.therefore:ambirix should be used only when there is a relatively low risk of hepatitis-b infection during the vaccination course;it is recommended that ambirix should be administered in settings where completion of the two-dose vaccination course can be assured.

European Union - English - EMA (European Medicines Agency)

novartis vaccines and diagnostics s.r.l. - influenza virus surface antigens (haemagglutinin and neuraminidase) of strain: a/california/7/2009 (h1n1)-derived strain used nymc x-181 - influenza, human; immunization; disease outbreaks - influenza vaccines - prophylaxis of influenza caused by a (h1n1v) 2009 virus.focetria should be used in accordance with official guidance.

European Union - English - EMA (European Medicines Agency)

glaxosmithkline biologicals s.a. - hepatitis a virus (inactivated), hepatitis b surface antigen - hepatitis b; hepatitis a; immunization - vaccines - twinrix adult is indicated for use in non immune adults and adolescents 16 years of age and above who are at risk of both hepatitis a and hepatitis b infection.

United States - English - NLM (National Library of Medicine)

grifols usa, llc - human hepatitis b virus immune globulin (unii: xii270yc6m) (human hepatitis b virus immune globulin - unii:xii270yc6m) - human hepatitis b virus immune globulin 220 [iu] in 1 ml - recommendations on post-exposure prophylaxis are based on available efficacy data and on the likelihood of future hbv exposure for the person requiring treatment. in all exposures, a regimen combining hepatitis b immune globulin (human) with hepatitis b vaccine will provide both short- and long-term protection, will be less costly than the two-dose hepatitis b immune globulin (human) treatment alone, and is the treatment of choice.(9) hyperhep b  is indicated for post-exposure prophylaxis in the following situations: after either parenteral exposure, e.g., by accidental “needlestick” or direct mucous membrane contact (accidental splash), or oral ingestion (pipetting accident) involving hbsag-positive materials such as blood, plasma or serum. for inadvertent percutaneous exposure, a regimen of two doses of hepatitis b immune globulin (human), one given after exposure and one a month later, is about 75% effective in preventing hepatitis b in this setting. infants born to hbsag-positive mothers are at risk of be

Australia - English - Department of Health (Therapeutic Goods Administration)

seqirus pty ltd - influenza virus haemagglutinin -

Australia - English - Department of Health (Therapeutic Goods Administration)

csl behring australia pty ltd - hepatitis b immunoglobulin, quantity: 400 iu; human immunoglobulin g, quantity: 160 mg/ml - injection, solution - excipient ingredients: glycine; water for injections; human immunoglobulin a - hepatitis b immunoglobulin-vf is indicated for post-exposure prophylaxis in persons who did not receive prior vaccination, or whose prior vaccination regimen is incomplete, or when the hepatitis b antibody level is inadequate (<10iu/l). post-exposure prophylaxis should be considered following percutaneous or permucosal exposure to hbsag-positive or suspected hbsag-positive material, for example, by needle stick, oral ingestion or sexual exposure. hepatitis b immunoglobulin-vf is also indicated for prophylaxis in infants born to hbsag-positive mothers.

European Union - English - EMA (European Medicines Agency)

vbi vaccines b.v. - hepatitis b surface antigen - hepatitis b - vaccines - prehevbri is indicated for active immunisation against infection caused by all known subtypes of the hepatitis b virus in adults. it can be expected that hepatitis d will also be prevented by immunisation with prehevbri as hepatitis d (caused by the delta agent) does not occur in the absence of hepatitis b infection. the use of prehevbri should be in accordance with official recommendations.,

New Zealand - English - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - hepatitis a vaccine 720 eu/ml;  ; hepatitis b surface antigen, recombinant 20 µg/ml; hepatitis a vaccine 720 eu/ml; hepatitis b surface antigen, recombinant 20 µg/ml - suspension for injection - active: hepatitis a vaccine 720 eu/ml   hepatitis b surface antigen, recombinant 20 µg/ml excipient: aluminium amino acids formaldehyde neomycin sulfate phenoxyethanol polysorbate 20 sodium chloride water for injection active: hepatitis a vaccine 720 eu/ml hepatitis b surface antigen, recombinant 20 µg/ml excipient: aluminium amino acids dibasic sodium phosphate monohydrate formaldehyde monobasic sodium phosphate dihydrate neomycin sulfate polysorbate 20 sodium chloride trometamol water for injection - twinrix is indicated for active immunisation against hepatitis a and hepatitis b virus infection in adults. twinrix is also indicated for active immunisation against hepatitis a and hepatitis b virus infection in infants, children and adolescents from 1 year up to and including 15 years of age at risk of, or who wish to be protected against, both infections.